Seminal studies showed that CRISPR-Cas systems provide adaptive immunity in prokaryotes and promising gene-editing tools from bacteria to humans. Yet, reports diverged on whether some CRISPR systems naturally target DNA or RNA. Here, Samai and colleagues unify the studies, showing that a single type III CRISPR-Cas system cleaves both DNA and RNA targets, independently.
Just a decade ago, clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes were poorly understood genomic loci documented in almost all archaea and many bacteria (van der Oost et al., 2014) . With no known function, the prevalence of these loci across highly compact prokaryotic genomes remained puzzling. Perhaps the only clue came from the observation by three groups that known CRISPR ''spacer'' sequences often matched viral and plasmid sequences (Makarova et al., 2006) . This bioinformatic observation led to the hypothesis that CRISPR-Cas loci may be prokaryotic adaptive immune systemscontinually incorporating new spacer sequences from viral genomes and storing these spacers to cleave complementary viral RNAs in subsequent infections through an antisense mechanism akin to eukaryotic RNA interference (Makarova et al., 2006) . Remarkably, the adaptive immunity hypothesis was validated in viral challenge experiments a year later (Barrangou et al., 2007) and was subsequently later generalized to the two other modes of genomic invasion in prokaryotes: conjugation and transformation (Marraffini and Sontheimer, 2008; van der Oost et al., 2014 ).
Yet, the emerging experimental picture of CRISPR as an antisense adaptive immune system differed from the early bioinformatic predictions in one mechanistic respect: spacers appeared to target foreign DNA rather than RNA (Marraffini and Sontheimer, 2008) . The only potential exceptions to DNA interference occurred in a subset of CRISPR-Cas systems known as type III systems, where the field split on whether DNA (Hatoum-Aslan et al., 2014; Marraffini and Sontheimer, 2008) or RNA (Hale et al., 2009; Staals et al., 2014; Tamulaitis et al., 2014 ) is targeted. A study in this issue of Cell (Samai et al., 2015) now resolves this debate-elegantly showing that a single type III system cleaves both DNA and RNA, via independent active sites ( Figure 1) . Samai et al. (2015) build on a series of seminal in vivo studies by Marraffini and colleagues, which employed the type III system encoded by a pathogenic isolate (RP162A) of the bacterium Staphylococcus epidermis. These earlier studies showed that a type III locus can inhibit plasmid establishment and the attendant spread of antibiotic resistance, provided that a spacer sequence matches a plasmid DNA sequence (Hatoum-Aslan et al., 2014; Marraffini and Sontheimer, 2008 ). Yet, spacer identity with plasmid RNA transcripts was shown to be insufficient for anti-plasmid immunity without DNA identity. Taken together, the in vivo data indicated that type III CRISPR systems confer immunity by targeting foreign DNA; however, a direct demonstration of DNA cleavage by a type III CRISPR system had never been performed.
To directly assess whether a type III CRISPR system cleaves complementary DNA, Samai et al. (2015) purify the Cas10-Csm effector complex, which mediates immunity in S. epidermis (Hatoum-Aslan et al., 2014) . The ribonucleoprotein complex consists of five proteins-Cas10, Csm2, Csm3, Csm4, and Csm5-as well as a processed spacer RNA that serves as a guide RNA. Strikingly, the authors initially capture no cleavage of DNA oligonucleotides complementary to the spacer RNA. Only when they induce transcription of the DNA targets-using an oligonucleotide-based system that enables elongation via RNA polymerase (RNAP)-is DNA cleavage seen. As a control, they also use a small-molecule inhibitor to block RNAP elongation. Consistent with transcription dependence, inhibiting RNAP elongation inhibits DNA cleavage.
In addition to providing a mechanism for DNA interference in vivo, transcription dependence may explain the lack of DNA cleavage observed in previous studies. In fact, the earlier in vitro studies only demonstrated RNA targeting and cleavage (Hale et al., 2009; Staals et al., 2014; Tamulaitis et al., 2014) . Matching these studies, when Samai et al. (2015) pit their purified Cas10-Csm complex against complementary RNA sequences, they also observe RNA cleavage. However, the authors go further and decouple the molecular drivers of DNA and RNA cleavage, showing that DNA cleavage requires an intact palm polymerase domain in Cas10, while RNA cleavage requires an independent active site in Csm3. As a result, DNA cleavage can be mutationally inactivated with no impact on RNA cleavage, and vice versa. By demonstrating that a single CRISPR complex independently cleaves both RNA and DNA, Samai and colleagues generalize (rather than contradict) the existing model of RNA-targeted immunity in type III systems.
From an evolutionary standpoint, the distinct RNA and DNA cleavage sites imply that both RNA and DNA targeting have been independently conserved by natural selection. Yet, the in vivo data of Samai et al. (2015) lead one to question why RNA interference has been preserved. When the authors test RNA interference alone-by only mutationally abrogating DNA interference-they find that plasmid establishment and cell death due to DNA phage infection are only minimally reduced. While a previous study did find that RNA targeting provides robust immunity against an RNA phage in a singleround viral challenge assay (Tamulaitis et al., 2014) , maintaining long-term immunity against RNA phages in the wild with a sequence-specific CRISPR system could prove difficult. RNA phages have mutation rates that are approximately three logs higher than dsDNA phages, implying that an anti-RNA CRISPR system would need to acquire new spacers extremely rapidly to stay apace (Weinberger et al., 2012) . And even if long-term immunity against RNA phages could be maintained in the wild (or in a chemostat), RNA phages are estimated to represent just 1% of the total phage population.
Another possibility is that the conserved RNA targeting pathway may be directed at DNA phages and plasmids, rather than RNA phages. RNA targeting could thus provide a built-in redundancy to DNA targeting-enabling a type III CRISPR system to cleave mRNA transcripts in case it misses the cognate DNA sequence. Supporting this hypothesis, the data in Samai et al. (2015) do show that mRNA cleavage increases the probability of bacterial survival during DNA phage infection, although mRNA cleavage is orders of magnitude less protective than DNA cleavage. If this increase in bacterial fitness accounts for the conservation of RNA targeting in type III systems, it will be interesting to see whether future studies uncover similar RNA-targeting mechanisms in type I or II systems. (Hale et al., 2009; Staals et al., 2014; Tamulaitis et al., 2014) . Notably, both Csm3 and Cas10 (discussed below) reside in the larger Cas10-Csm complex, which is not shown for simplicity. (B) The competing model in which complementary DNA, rather than RNA, is targeted (Marraffini and Sontheimer, 2008) . In vivo, CRISPR targeting of DNA had been shown to require Cas10 (Hatoum-Aslan et al., 2014 ), yet in vitro demonstrations of DNA cleavage remained elusive. (C) The unified model proposed by Samai et al. (2015) , in which a single type III CRISPR-Cas system cleaves both complementary DNA (via Cas10) and RNA (via Csm3). Notably, DNA cleavage is transcription dependent and only occurs on the non-template strand. The broad tropism for both DNA and RNA targets may provide a critical evolutionary advantage.
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